89bio, Inc/$ETNB
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About 89bio, Inc
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Ticker
$ETNB
Sector
Primary listing
Employees
93
Headquarters
Website
89bio, Inc Metrics
BasicAdvanced
$1.4B
-
-$3.41
1.36
-
Price and volume
Market cap
$1.4B
Beta
1.36
52-week high
$11.84
52-week low
$4.16
Average daily volume
1.5M
Financial strength
Current ratio
15.186
Quick ratio
14.167
Long term debt to equity
7.06
Total debt to equity
7.21
Interest coverage (TTM)
-71.06%
Profitability
EBITDA (TTM)
-423.239
Effective tax rate (TTM)
-0.30%
Management effectiveness
Return on assets (TTM)
-49.10%
Return on equity (TTM)
-86.86%
Valuation
Price to book
2.61
Price to tangible book (TTM)
2.22
Price to free cash flow (TTM)
-2.759
Free cash flow yield (TTM)
-36.24%
Free cash flow per share (TTM)
-3.33
Growth
Earnings per share change (TTM)
72.52%
3-year earnings per share growth (CAGR)
-13.05%
What the Analysts think about 89bio, Inc
Analyst ratings (Buy, Hold, Sell) for 89bio, Inc stock.
89bio, Inc Financial Performance
Revenues and expenses
89bio, Inc Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for 89bio, Inc stock?
89bio, Inc (ETNB) has a market cap of $1.4B as of September 03, 2025.
What is the P/E ratio for 89bio, Inc stock?
The price to earnings (P/E) ratio for 89bio, Inc (ETNB) stock is 0 as of September 03, 2025.
Does 89bio, Inc stock pay dividends?
No, 89bio, Inc (ETNB) stock does not pay dividends to its shareholders as of September 03, 2025.
When is the next 89bio, Inc dividend payment date?
89bio, Inc (ETNB) stock does not pay dividends to its shareholders.
What is the beta indicator for 89bio, Inc?
89bio, Inc (ETNB) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.